

# R&D DAY

THERAPEUTIC VACCINES & ONCOLYTIC VIRUSES  
TO FIGHT AGAINST CANCER

**Tuesday September 27, 2022**

2 pm – 6 pm CET | 8 am – 12 pm EST

## PROGRAM

**2:00 pm – 2:10 pm | Introduction** - *Hedi Ben Brahim, CEO Transgene*

**2:10 pm – 4:00 pm | Therapeutic vaccines**

- 2:10 pm | **Therapeutic vaccines: ideal modalities to answer multiple medical needs** - *Maud Brandely, CMO - Transgene*
- 2:15 pm | **Viral vectors can be key in the therapeutic arsenal** - *Éric Quéméneur, CSO - Transgene*
- 2:25 pm | **TG4001- a HPV16 therapeutic vaccine in Phase II** - *Jean-Pierre Delord, MD, PhD - IUCT Oncopole of Toulouse*
- 2:40 pm | **AI in cancer treatment** - *Kaïdre Bendjama - Transgene*
- 2:55 pm | **From the design of the *myvac*<sup>®</sup> platform to first immunological and clinical readouts, Update on the head and neck trial of TG4050** - *Christian Ottensmeier, MD, PhD, FRCP - University of Liverpool, The Clatterbridge Cancer Center NHS Foundation Trust*
- 3:30 pm | **Personalized therapeutic vaccine in the treatment of ovarian cancer** - *Matthew S. Block, MD, PhD - Mayo Clinic*
- 3:45 pm | **Wrap up and Q&A**

**4:15 pm – 5:25 pm | Oncolytic viruses (OVs)**

- 4:15 pm | **Using Transgene's OV's in cancer therapy** - *Éric Quéméneur, CSO - Transgene*
- 4:30 pm | **Assessing novel routes of administration (IV/locoregional routes) with TG6002** - *Adel Samson, MD, PhD - University of Leeds*
- 4:50 pm | **Invir.IO™: what's next?** - *Eric Quéméneur, CSO - Transgene*
- 5:05 pm | **Invir.IO™, a versatile platform enabling multiple collaboration and future potential revenue** - *Steve Bloom, CBO - Transgene*
- 5:15 pm | **Wrap up and Q&A**

**5:25 pm | Business, scientific, and medical perspective - Conclusion**

- 5:25 pm | **Opportunities in the immuno-oncology field** - *Pedro Romero, MD - JITC, Ludwig Institute for Cancer research (Lausanne)*
- 5:45 pm | **Conclusion** - *Hedi Ben Brahim, CEO - Transgene*

The conference will be held in English.

The event will be accessible online to everyone on Transgene's website and via [webcast](#). Investment professionals are welcome to attend in person and will receive details upon registration. Please sign up via this link <https://bit.ly/3Ucycsr>.